CRISPR Therapeutics' (CRSP) "Buy" Rating Reaffirmed at Chardan Capital

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $82.00 price objective on the stock. Chardan Capital's target price would suggest a potential upside of 76.38% from the company's current price.

CRSP has been the topic of a number of other reports. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. Barclays lowered their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. JMP Securities reissued a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, May 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $69.53.

CRISPR Therapeutics Stock Down 2.5%

Shares of CRSP traded down $1.17 during trading on Thursday, reaching $46.49. 804,680 shares of the company traded hands, compared to its average volume of 1,789,852. The stock has a 50-day simple moving average of $39.10 and a 200-day simple moving average of $40.58. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $63.68. The stock has a market cap of $4.01 billion, a PE ratio of -10.27 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period last year, the firm earned ($1.43) EPS. CRISPR Therapeutics's quarterly revenue was up 71.6% compared to the same quarter last year. On average, equities research analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider now owns 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CRSP. SVB Wealth LLC acquired a new stake in shares of CRISPR Therapeutics in the 1st quarter worth $25,000. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at about $30,000. Costello Asset Management INC purchased a new stake in CRISPR Therapeutics in the 1st quarter valued at approximately $27,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics during the 4th quarter worth approximately $36,000. Finally, Quantbot Technologies LP increased its position in CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock worth $45,000 after purchasing an additional 978 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.